Attenuated immune response to tetanus toxoid in young healthy men protected against tetanus.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 15985319)

Published in Vaccine on October 10, 2005

Authors

Elena Danilova1, Alexey Shiryayev, Einar Klaeboe Kristoffersen, Haakon Sjursen

Author Affiliations

1: Institute of Medicine, Centre for International Health, University of Bergen, Norway.

Associated clinical trials:

Entolimod, an Adjuvant for Vaccine Augmentation | NCT03063736

Articles by these authors

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine (2009) 1.80

Should patients who use illicit drugs be offered a second heart-valve replacement? Tidsskr Nor Laegeforen (2013) 1.46

[Risk of infection through use of selective immunomodulating drugs for rheumatoid arthritis]. Tidsskr Nor Laegeforen (2012) 1.39

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine (2010) 1.32

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine (2011) 1.18

T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis (2012) 1.14

Tickborne encephalitis virus, Norway and Denmark. Emerg Infect Dis (2006) 0.98

Molecular characterization of Corynebacterium diphtheriae isolates, Russia, 1957-1987. Emerg Infect Dis (2002) 0.87

The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol (2009) 0.82

Incidence, clinical characteristics and outcome in Norwegian children with periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome; a population-based study. Acta Paediatr (2012) 0.82

Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. Hum Vaccin Immunother (2014) 0.82

Short-term booster effect of diphtheria toxoid in initially long-term protected individuals. Vaccine (2005) 0.81

[Aminoglycosides should still be used in empirical sepsis treatment]. Tidsskr Nor Laegeforen (2013) 0.77

[Hepatitis C in Northern Norway--an 8-year material]. Tidsskr Nor Laegeforen (2002) 0.76

Antidiphtheria antibody responses in patients and carriers of Corynebacterium diphtheriae in the Arkhangelsk region of Russia. Clin Vaccine Immunol (2006) 0.76

[Use of a new antibiotic in Norway]. Tidsskr Nor Laegeforen (2007) 0.75

[Periodic fever syndrome in children]. Tidsskr Nor Laegeforen (2007) 0.75

[A man with pain following a knee operation]. Tidsskr Nor Laegeforen (2012) 0.75

Co-occurrence of Epstein-Barr virus infection and ascites in sarcoidosis. Scand J Infect Dis (2004) 0.75

Seroprotection against diphtheria and tetanus among Russian and Norwegian teenagers. APMIS (2006) 0.75